These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 32459922)

  • 1. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.
    Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP
    N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
    Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
    PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin Ligase Activities of WWP1 Germline Variants K740N and N745S.
    Jiang H; Dempsey DR; Cole PA
    Biochemistry; 2021 Feb; 60(5):357-364. PubMed ID: 33470109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
    Bennett KL; Mester J; Eng C
    JAMA; 2010 Dec; 304(24):2724-31. PubMed ID: 21177507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer risk and clinical implications for germline PTEN mutation carriers.
    Ngeow J; Sesock K; Eng C
    Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer.
    Ngeow J; Ni Y; Tohme R; Song Chen F; Bebek G; Eng C
    J Clin Endocrinol Metab; 2014 Jul; 99(7):E1316-21. PubMed ID: 24712574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?
    Mester JL; Moore RA; Eng C
    Oncologist; 2013; 18(10):1083-90. PubMed ID: 24037976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants.
    Brewer T; Yehia L; Bazeley P; Eng C
    Am J Hum Genet; 2022 Aug; 109(8):1520-1533. PubMed ID: 35931053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.
    Ngeow J; Eng C
    Methods; 2015 May; 77-78():11-9. PubMed ID: 25461771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model.
    Mester JL; Tilot AK; Rybicki LA; Frazier TW; Eng C
    Eur J Hum Genet; 2011 Jul; 19(7):763-8. PubMed ID: 21343951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifetime cancer risks in individuals with germline PTEN mutations.
    Tan MH; Mester JL; Ngeow J; Rybicki LA; Orloff MS; Eng C
    Clin Cancer Res; 2012 Jan; 18(2):400-7. PubMed ID: 22252256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes.
    Ni Y; Zbuk KM; Sadler T; Patocs A; Lobo G; Edelman E; Platzer P; Orloff MS; Waite KA; Eng C
    Am J Hum Genet; 2008 Aug; 83(2):261-8. PubMed ID: 18678321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of cancer-prone germline PTEN mutant mice¬†with low-dose rapamycin extends lifespan and delays tumour development.
    Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
    J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copy Number Variation and Clinical Outcomes in Patients With Germline PTEN Mutations.
    Yehia L; Seyfi M; Niestroj LM; Padmanabhan R; Ni Y; Frazier TW; Lal D; Eng C
    JAMA Netw Open; 2020 Jan; 3(1):e1920415. PubMed ID: 32003824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.
    Orloff MS; Eng C
    Oncogene; 2008 Sep; 27(41):5387-97. PubMed ID: 18794875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.
    Pezzolesi MG; Li Y; Zhou XP; Pilarski R; Shen L; Eng C
    Am J Hum Genet; 2006 Nov; 79(5):923-34. PubMed ID: 17033968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline PTEN mutations in Cowden syndrome-like families.
    Marsh DJ; Dahia PL; Caron S; Kum JB; Frayling IM; Tomlinson IP; Hughes KS; Eeles RA; Hodgson SV; Murday VA; Houlston R; Eng C
    J Med Genet; 1998 Nov; 35(11):881-5. PubMed ID: 9832031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation?
    Yehia L; Eng C
    Hum Mol Genet; 2020 Oct; 29(R2):R150-R157. PubMed ID: 32568377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebellar phenotypes in germline PTEN mutation carriers.
    Gambini D; Ferrero S; Bulfamante G; Pisani L; Corbo M; Kuhn E
    Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12970. PubMed ID: 38504418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.
    Ngeow J; He X; Mester JL; Lei J; Romigh T; Orloff MS; Milas M; Eng C
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2320-7. PubMed ID: 23066114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.